Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

PHASE3CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

April 14, 2021

Study Completion Date

April 14, 2021

Conditions
Cataract
Interventions
DRUG

Clobetasol Propionate

Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)

DRUG

Vehicle

Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance

Trial Locations (18)

23512

Virgina Eye Consultants, Norfolk

30339

Eye Consultants of Atlanta, Atlanta

32174

International Eye Associates, PA, Ormond Beach

32204

Levenson Eye Associates, Jacksonville

63090

Comprehensive Eye Care Ltd, Washington

63131

Ophalmology Associates, St Louis

66762

Kannarr Eye Care, Pittsburg

77008

Houston Eye Associates, Houston

78212

Braverman-Terry-Oei Eye Associates, San Antonio

85225

Walman Eye Center, Sun City

89052

NV Eyey Surgery, Henderson

90301

United Medical Research Institute, Inglewood

92595

Inland Eye Specialists, Hemet

92663

Visionary Eye Institute, Newport Beach

94954

North Bay Eye, Petaluma

33321-2934

Andrew Gardner Logan dba Ophthalmic Research LLC, Tamarac

78572-2424

Shah Eye Center, Mission

84117-5209

Stacy R. Smith, M.D., P.C., Salt Lake City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Salvat

INDUSTRY